# A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

> **NCT06241846** · PHASE2 · RECRUITING · sponsor: **MediLink Therapeutics (Suzhou) Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** YL201 for Injection

## Key facts

- **NCT ID:** NCT06241846
- **Lead sponsor:** MediLink Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-22
- **Primary completion:** 2027-02
- **Final completion:** 2029-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06241846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06241846, "A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT06241846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*